Trial site
Azienda Socio Sanitaria Territoriale Della Valle Olona
Saronno, 21047, ItalyNot linked to an institution yet
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 34 trials
- Phase 2/31 trial
- Status
- Not yet recruiting5 trials
- Active, not recruiting3 trials
- Recruiting3 trials
- Lead sponsor
- Fondazione Ricerca Traslazionale2 trials
- Regeneron Pharmaceuticals2 trials
- Anthos Therapeutics, Inc.1 trial
- Consorzio Oncotech1 trial
- Dompe' Farmaceutici S.p.A.1 trial
- and 4 more
Running trials
Not yet recruiting
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:”
“A multi-arms prospective, randomized phase II study to evaluate the best sequential
therapeutic strategis in patients with metastatic non-small cell lung cancer harboring
targetable genomic driver alterations”
2026-525268-16-00· Phase 2/3· Universita' Degli Studi Di Torino· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants with moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00· Phase 2· Dompe' Farmaceutici S.p.A.· Source
Not yet recruiting
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
NCT07418931· Phase 2· Gruppo Oncologico Italiano di Ricerca Clinica· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Patiromer and Diet/hrQoL in Chronic Dialysis
NCT06858280· Phase 3· Mario Negri Institute for Pharmacological Research· Source
Recruiting
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET
deregulation
NCT03911193· Phase 2· Fondazione Ricerca Traslazionale· Source
Active, not recruiting
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05817903· Phase 2· Consorzio Oncotech· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Recruiting
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
NCT04811001· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error